Healthcare
Standard BioTools Inc.(LAB)
Live Price
Offline$0.89
-2.20% today
1Y Change
-32.13%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $360.00M
- Revenue Growth
- -51.1%
- EPS Growth
- +61.5%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Standard BioTools Inc. (LAB) is a Healthcare stock with a market cap of $360.00M and listed on NASDAQ. The stock last traded around $0.89 and down 32.1% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -51.1%, EPS growth of +61.5%, a dividend yield of 0.0%. What stands out right now is revenue -51.1%, EPS +61.5%, free cash flow +45.6% with operating margin -109.3% and ROIC -12.2%. Valuation sits in the middle of the pack at price/sales 4.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LAB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-51.1% vs +7.6% peer median
Operating Margin
Below sector median
-109.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -51.1% and EPS is at +61.5%, with operating margin around -109.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -1.0% | +3.1% | +16.3% |
2026 Feb 24, 2026 | +300.0% | +1.7% | -9.6% | -17.4% |
2025 Nov 4, 2025 | -60.0% | -4.2% | +0.0% | +21.0% |
Benchmark Edge
LAB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LAB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LAB Max Drawdown
-52.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LAB and SPY.
Company Overview
Standard BioTools Inc.
NASDAQ Global Select
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
- Leadership
- Michael Egholm
- IPO Date
- Feb 10, 2011
- Employees
- 814
- Street Address
- 2 Tower Place
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 266 6000
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.3
- Price/Book
- 0.8
Growth
- Revenue
- -51.1%
- EPS
- +61.5%
- Free Cash Flow
- +45.6%
Profitability
- Gross Margin
- 49.9%
- Operating Margin
- -109.3%
- Net Margin
- -87.8%
- ROE
- -17.6%
- ROIC
- -12.2%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 4.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.